AgingResearch.NewsJoin free

MetaVia

CompanyUnited States

MetaVia develops one asset, in phase 1 (DA-1726 in obesity). Mostly peptide acting on GLP1R and GCGR; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
1
Signal

Pipeline

1

  • DA-1726

    Oxyntomodulin analogue that activates GLP-1 and glucagon receptors to promote weight loss.

    Phase 1, Peptide, GLP1R, GCGR, obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals3
  • Similar companies6

Papers

Intelligence